Scholar Rock to Present at Upcoming Investor Conferences
Business Wire•03/11/2026•08:00 ET
0
Key Highlights
- ➤Scholar Rock (SRRK) to present at UBS Global Biopharma Conference on November 16, 2026
- ➤Scholar Rock (SRRK) to present at Jefferies Global Healthcare Conference on November 17, 2026
- ➤FDA approved ISEMBLYD (apitegromab-mstn) in September 2026 for U.S. SMA patients
- ➤Scholar Rock plans to expand ISEMBLYD access globally across up to 50 countries
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today announced that management will participate in the following investor conferences:
* UBS Global Biopharma Conference 2026: Scholar Rock is scheduled to participate in a fireside chat at 10:00 a.m. GMT / 5:00 a.m. ET on Monday, November 16, 2026 in London.
Get started
Create a free account to read the full story.